FY26 Results: Revenue declines 6%, PAT up 3.6% YoY
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Colinz Laboratories reported FY26 revenue from operations of Rs 613.61 lakhs, down 6% from Rs 652.77 lakhs in FY25. PAT rose to Rs 51.45 lakhs vs Rs 49.66 lakhs (+3.6%). Q4 FY26 showed strong recovery with revenue at Rs 174.79 lakhs (+20% YoY) and PAT at Rs 17.12 lakhs. Operating cash flow swung to positive Rs 254.11 lakhs from negative Rs 145.37 lakhs. Cash position strengthened to Rs 852.91 lakhs. Auditor issued unqualified opinion.
Mixed results: full-year revenue declined, but profitability and cash flows improved. Q4 momentum is a positive signal.